Last update 05 Jul 2025

Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
GR 1401, GR-1401, GR1401
+ [1]
Target
EGFR
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases
Active Indication-
Inactive Indication
Advanced cancerColorectal CancerEsophageal Carcinoma+ [1]
Originator Organization
Shanghai Union Biopharm Co., Ltd.Shanghai Union Biopharm Co., Ltd.
Active Organization-
Inactive Organization
Chongqing Genrix Biopharmaceutical Co., Ltd.Chongqing Genrix Biopharmaceutical Co., Ltd.
License Organization
Zhixiang (Shanghai) Medical Technology Co., Ltd.Zhixiang (Shanghai) Medical Technology Co., Ltd.Shaanxi Zhonghe Pharmaceutical Co., Ltd.Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)
CTR20170941
/ TerminatedPhase 1
GR1401在晚期肿瘤患者中的耐受性、药代动力学、免疫原性、剂量递增的安全性、初步疗效评价的I期临床试验
[Translation] Phase I clinical trial of GR1401 in patients with advanced tumors to evaluate its tolerability, pharmacokinetics, immunogenicity, safety of dose escalation, and preliminary efficacy
100 Clinical Results associated with Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)
Login to view more data
100 Deals associated with Recombinant human anti-EGFR mAB(Shanghai Union Biopharm Co., Ltd.)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 1
China
Chongqing Genrix Biopharmaceutical Co., Ltd.Chongqing Genrix Biopharmaceutical Co., Ltd.
21 Aug 2017
Colorectal CancerPhase 1
China
Chongqing Genrix Biopharmaceutical Co., Ltd.Chongqing Genrix Biopharmaceutical Co., Ltd.
21 Aug 2017
Esophageal CarcinomaPhase 1
China
Chongqing Genrix Biopharmaceutical Co., Ltd.Chongqing Genrix Biopharmaceutical Co., Ltd.
21 Aug 2017
Non-Small Cell Lung CancerPhase 1
China
Chongqing Genrix Biopharmaceutical Co., Ltd.Chongqing Genrix Biopharmaceutical Co., Ltd.
21 Aug 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free